Title |
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
|
---|---|
Published in |
OncoTargets and therapy, May 2016
|
DOI | 10.2147/ott.s102472 |
Pubmed ID | |
Authors |
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuankai Shi |
Abstract |
The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded. For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment. Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 10% |
Unknown | 9 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 2 | 20% |
Student > Ph. D. Student | 2 | 20% |
Other | 1 | 10% |
Researcher | 1 | 10% |
Student > Master | 1 | 10% |
Other | 0 | 0% |
Unknown | 3 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 2 | 20% |
Biochemistry, Genetics and Molecular Biology | 1 | 10% |
Medicine and Dentistry | 1 | 10% |
Unknown | 6 | 60% |